Methylprednisolone
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1957
- First approval year
- 1957
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Methylprednisolone
- Molecular weight
- 374.48
- Structure (SMILES)
- C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12
- medrol
- Medrol
- medrone
- Medrone
- methylprednisolone
- Methylprednisolone
- methylprednisolone component of neo medrol
- Methylprednisolone component of neo-medrol
- 6 methyl prednisolone
- 6 methyl prednisolone steroids for group a
- 6 methylprednisolone
- 6-methyl prednisolone (Steroids) (for Group A)
- 6-methyl prednisolone (Steroids) (for Group B)
- 6-methyl-prednisolone
- 6-methylprednisolone
- j3 872e
- J3.872E
- methylprednisolone
- Methylprednisolone
- METHYLPREDNISOLONE [EP MONOGRAPH]
- METHYLPREDNISOLONE [GREEN BOOK]
- METHYLPREDNISOLONE [HSDB]
- methylprednisolone [INN]
- METHYLPREDNISOLONE [JAN]
- METHYLPREDNISOLONE [MART.]
- METHYLPREDNISOLONE [MI]
- METHYLPREDNISOLONE [ORANGE BOOK]
- METHYLPREDNISOLONE [USP MONOGRAPH]
- METHYLPREDNISOLONE [USP-RS]
- METHYLPREDNISOLONE [VANDF]
- Methylprednisolone [WHO-DD]
- METHYLPREDNISOLONE ACETATE IMPURITY B [EP IMPURITY]
- methylprednisolone acetate impurity b ep impurity
And 22 more, listed on the interactive page.
- CAS registry numbers
- 83-43-2
- ChEMBL ID
- CHEMBL650
- InChIKey
- VHRSUDSXCMQTMA-PJHHCJLFSA-N
- PubChem compound IDs
- 6741
- FDA ingredient codes (UNII)
- X4W7ZR7023
- D07AA01
- D10AA02
- H02AB04
- H02BX01
Sources for recorded values
- 6902
- 155323
- Applicant
- PFIZER
- Approval date
- 24 Oct 1957
- Application number
- NDA011153
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- methylprednisolone
- Type
- Metabolite
- Drug name stem
- -olone; -pred-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- topical
- Action
- Activation
- Action type
- ACTIVATION
- Target
- TRPC5
- Gene symbol
- TRPC5
- Protein identifier
- Q9UL62
- Median affinity
- 4.92
- Affinity units
- pEC50
- Action
- Agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 8.3
- Affinity units
- pKi
- Primary target
- Yes
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Protein identifier
- P04150
Open Targets mechanisms
- Mechanism
- Glucocorticoid receptor agonist
- Action type
- Agonist
- Target
- Glucocorticoid receptor
- Action type
- ACTIVATOR
- Gene symbol
- TRPC5
- Protein identifier
- Q9UL62
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Action type
- Agonist
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Crohn Disease
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Immune System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Wounds and Injuries
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Dermatomyositis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000557
- Subject identifier
- D003882
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Adenomatous Polyposis Coli
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000662
- Subject identifier
- D011125
- Condition
- Respiratory Tract Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000684
- Subject identifier
- D012140
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Spondylarthropathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000706
- Subject identifier
- D025242
And 131 more, listed on the interactive page.
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000266
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0000540
- Condition identifier
- EFO_0000546
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000684
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000685
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000714
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000717
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001379
- Condition identifier
- EFO_0002609
- Condition identifier
- EFO_0003046
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003103
- Highest recorded phase
- 3
And 391 more, listed on the interactive page.
- Event
- abdominal discomfort
- Reports
- 3,062
- Reporting signal score
- 1,819.65
- Event
- alopecia
- Reports
- 3,180
- Reporting signal score
- 1,945.35
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 1,133
- Reporting signal score
- 2,768.74
- Event
- arthropathy
- Reports
- 2,025
- Reporting signal score
- 1,683.61
- Event
- bk virus infection
- Reports
- 161
- Reporting signal score
- 388.58
- Event
- bronchopulmonary aspergillosis
- Reports
- 154
- Reporting signal score
- 299.693
- Event
- cushingoid
- Reports
- 129
- Reporting signal score
- 279.701
- Event
- cytomegalovirus infection
- Reports
- 2,002
- Reporting signal score
- 3,255.14
- Event
- cytomegalovirus infection reactivation
- Reports
- 123
- Reporting signal score
- 312.542
- Event
- cytomegalovirus viraemia
- Reports
- 187
- Reporting signal score
- 451.638
- Event
- diabetes mellitus
- Reports
- 343
- Reporting signal score
- 275.823
- Event
- epstein-barr virus infection
- Reports
- 182
- Reporting signal score
- 356.186
- Event
- febrile neutropenia
- Reports
- 3,032
- Reporting signal score
- 2,352.98
- Event
- glossodynia
- Reports
- 2,026
- Reporting signal score
- 3,844.48
- Event
- graft versus host disease
- Reports
- 157
- Reporting signal score
- 302.729
- Event
- hand deformity
- Reports
- 1,695
- Reporting signal score
- 3,591.12
- Event
- hyperglycaemia
- Reports
- 311
- Reporting signal score
- 307.202
- Event
- kaposi's sarcoma
- Reports
- 149
- Reporting signal score
- 332.949
- Event
- kidney transplant rejection
- Reports
- 241
- Reporting signal score
- 573.59
- Event
- lymphocyte count decreased
- Reports
- 349
- Reporting signal score
- 509.041
- Event
- mucormycosis
- Reports
- 106
- Reporting signal score
- 283.851
- Event
- nocardiosis
- Reports
- 714
- Reporting signal score
- 1,673.8
- Event
- pemphigus
- Reports
- 2,586
- Reporting signal score
- 6,324.58
- Event
- pneumocystis jirovecii pneumonia
- Reports
- 1,327
- Reporting signal score
- 2,386.39
- Event
- polyomavirus-associated nephropathy
- Reports
- 756
- Reporting signal score
- 1,744.91
And 11 more, listed on the interactive page.
- NCT00000146
- NCT01524250
- NCT00000579
- NCT00000730
- NCT00000741
- NCT00002471
- NCT00002534
- NCT00002718
- NCT00002785
- NCT00002831
- NCT00003187
- NCT00003336
- NCT00003728
- NCT00003960
- NCT00004034
- NCT00004232
- NCT00004904
- NCT00006451
- NCT00008307
- NCT00022126
- NCT00400946
- NCT00458848
- NCT00553202
- NCT00609739
- NCT01005758
And 301 more, listed on the interactive page.
- Dose
- 30 mg/kg
- Route
- Intravenous, intramuscular
- How often
- Every 4 to 6 hours for 48 hours, or as needed
- Administer over at least 30 minutes
- Prepare as directed before use
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 3
- Polar surface area
- 94.83
- Calculated partition coefficient (ALogP)
- 1.8
- Calculated partition coefficient (XLogP)
- 1.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 27
- Molecular formula
- C22H30O5
- Monoisotopic mass
- 374.20932405
- Natural product
- Yes
- 0009-0020
- 0009-0022
- 0009-0056
- 0009-0073
- 0603-4593
- 0904-6914
- 42806-400
- 55289-649
- 57582-101
- 60760-961
- 62135-759
- 62135-760
- 62135-761
- 62135-762
- 62135-763
- 63187-160
- 68001-624
- 68084-149
- 68382-916
- 68382-917
- 68382-918
- 68382-919
- 69306-400
- 71205-453
- 72189-264
And 27 more, listed on the interactive page.
- Recorded assays
- 2,624
- Active assays
- 56
- Confirmatory
- Other
- Screening
- Summary
- Anti-Inflammatory Agents
- Antiemetics
- Glucocorticoids
- Neuroprotective Agents
These details could not be displayed.
Related records
Trials (715)
- "Steroids and Azathioprine Versus Steroids Alone in IgAN"
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI
- 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome
- 99Tc-MDP for Thyroid-Associated Ophthalmopathy
- A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy
- A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets
- A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions
- A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions
- A Comparative Study Between Dexmedetomidine Versus Methylprednisolone on Induced Inflammatory Response in Patients Undergoing On-pump CABG
- A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome
- A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis.
- A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study
- A Comparison of Ultrasound-guided Steroid Injection With Wrist Splint in Carpal Tunnel Syndrome
- A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
- A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
- A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
- a Phase II Study in Primary Central Nervous System Lymphoma
Approved for (16)
- Acne
- Asthma
- Atopic eczema
- Bursitis
- Crohn disease
- Endocrine system disorder
- Frozen shoulder
- Juvenile idiopathic arthritis
- Multiple sclerosis
- Osteoarthritis
- Pneumonia
- Posterior uveitis
- Psoriatic arthritis
- Rheumatoid arthritis
- Tenosynovitis
- Ulcerative colitis
In development for (128)
- 22q11.2 deletion syndrome Phase 1
- Acute lymphoblastic leukemia Phase 3
- Acute myocarditis Phase 3
- Acute respiratory distress syndrome Phase 3
- Adult acute respiratory distress syndrome Phase 3
- Alcoholic hepatitis Phase 2
- Amyotrophic lateral sclerosis Phase 2
- Anaplastic large cell lymphoma Phase 2
- Angioimmunoblastic T-cell lymphoma Phase 2
- Ankylosing spondylitis Phase 2
- Anterior ischemic optic neuropathy Phase 3
- Anti-neutrophil antibody associated vasculitis Phase 3
- Aplastic anemia Phase 2
- Appendicitis Phase 2
- Atherosclerosis Phase 1
- Autoimmune thrombocytopenic purpura Phase 3
- B-cell chronic lymphocytic leukemia Phase 2
- Bell's palsy Phase 3
- Bone marrow neoplasm Phase 2
- Breast cancer Phase 2
Other linked conditions (6)
- Acute graft versus host disease
- Autoimmune encephalitis
- Bronchiolitis
- Contact dermatitis
- Glomerular disorder
- Mycoplasma pneumoniae pneumonia
Targets (1)
- NR3C1 Glucocorticoid receptor agonist